Skip to main content

Advertisement

SpringerLink
Log in

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the use of preoperative intravitreal bevacizumab (IVB) in patients undergoing pars plana vitrectomy (PPV) for complications of proliferative diabetic retinopathy (PDR).

Methods

We studied 22 patients with severe PDR. A preoperative complexity score (CS) was recorded. Eleven eyes were treated with IVB, 1.25 mg, 5–7 days before PPV (group 1), and 11 eyes underwent direct PPV (group 2). Surgical time and intra-operative manoeuvres were recorded. Main outcome measure was feasibility of surgery, secondary goal was the visual and anatomic outcome at 6 months.

Results

The average CS was 5.5, and was similar in the two groups. Mean surgical time was 57 minutes in group 1 vs 83 minutes in group 2; mean tool exchanges was 27 vs 53, intraoperative bleeding 5 vs 15, endodiathermy 2 vs 9. No complications were recorded after IVB. Mean pre-operative BCVA was 1.87 logMAR in group 1 and logMAR 2.04 in group 2. Mean pre-operative BCVA was 1.87 logMAR in the bevacizumab group and 2.04 logMAR in group 2, not significantly different (p = 0.7). Mean post-operative BCVA at 6 months was 0.88 logMAR in group 1 and logMAR 2.01 in control group 2, significantly different (p = 0.01). Post-operative BVCA improved in bevacizumab group from pre-operative value (p = 0.15), while in control group there was non-significant increase (p = 0.96). Anatomical attachment was achieved in 11 patients in group 1 vs nine patients in group 2.

Conclusions

IVB administered prior to vitrectomy was well tolerated and reduced active neovascularization, thus facilitating PPV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Varma R, Torres M, Pena F et al (2004) Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology 111:1298–1306

    Article  PubMed  Google Scholar 

  2. Kempen JH, O'Colmain BJ, Leske MC et al (2004) The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122:552–563

    Article  PubMed  Google Scholar 

  3. Flynn HW Jr, Chew EY, Simons BD et al (1992) Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17.. Ophthalmology 99:1351–1357

    PubMed  Google Scholar 

  4. Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98:823–833

    Google Scholar 

  5. Vander JF, Duker JS, Benson WE et al (1991) Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 98:1575–1579

    PubMed  CAS  Google Scholar 

  6. Michaelson IC (1948) The mode of development the vascular system of the retina with some observation on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 68:137–180

    Google Scholar 

  7. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Medicine 331:1480–1487 Abstract

    Article  CAS  Google Scholar 

  8. Aiello LP, Pierce EA, Foley ED et al (1995) Suppression of retinal neovascularization in vivo by inhibition of Vascular endothelial growth factor(VEGF)using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457–10461

    Article  PubMed  CAS  Google Scholar 

  9. Tolentino MJ, McLeod DS, Taomoto M et al (2002) Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373–385

    Article  PubMed  CAS  Google Scholar 

  10. Tolentino MJ, Miller JW, Gragoudas ES et al (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964–970

    PubMed  CAS  Google Scholar 

  11. Tolentino MJ, Miller JW, Gragoudas ES et al (1996) Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103:1820–1828

    PubMed  CAS  Google Scholar 

  12. Adamis AP, Shima DT, Tolentino MJ et al (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66–71

    PubMed  CAS  Google Scholar 

  13. Adamis AP, Miller JW, Bernal MT et al (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450

    PubMed  CAS  Google Scholar 

  14. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  15. Adding a humanized antibody to vascular endothelial growth factor (bevacizumab, Bevacizumab) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 8:85–88

  16. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Article  PubMed  CAS  Google Scholar 

  17. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  18. Yang JC (2004) Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10:S6367–S6370

    Article  Google Scholar 

  19. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Bevacizumab) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047

    Article  PubMed  Google Scholar 

  20. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Bevacizumab) for neovascular age-related macular degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  21. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Bevacizumab) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:33133–33135

    Google Scholar 

  22. Nguyen QD, Shah S, Tatlipinar S et al (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368–1370

    Article  PubMed  CAS  Google Scholar 

  23. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Bevacizumab) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339

    PubMed  Google Scholar 

  24. Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Bevacizumab) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 26:279–284

    Article  PubMed  Google Scholar 

  25. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Bevacizumab) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

    Article  PubMed  Google Scholar 

  26. Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155–158

    Article  PubMed  CAS  Google Scholar 

  27. Chen E, Park CH (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26:699–700

    Article  PubMed  Google Scholar 

  28. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Bevacizumab) treatment. Retina 26:352–354

    Article  PubMed  Google Scholar 

  29. Avery RL, Pearlman J, Pieramici DJ et al (2006) Intravitreal bevacizumab (Bevacizumab) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:695–615

    Article  Google Scholar 

  30. Rodrigo J, Costa R, Calucci D et al (2006) Intravitreal Bevacizumab (Bevacizumab) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina 26:1006–1013

    Article  Google Scholar 

  31. Chobanian AV, Bakris GL, Black HR et al (2003) National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572. Erratum in: JAMA 2003;290:197

    Article  PubMed  CAS  Google Scholar 

  32. Grigorian RA, Castellarin A, Fegan R et al (2003) Epiretinal membrane removal in diabetic eyes: comparison of viscodissection with conventional methods of membrane peeling. Br J Ophthalmol 87:737–741

    Article  PubMed  CAS  Google Scholar 

  33. Ferrara N (2004) Vascular endothelial growth factor: basic science in clinical progress. Endocr Rev 25:581–611

    Article  PubMed  CAS  Google Scholar 

  34. Mordenti J, Cuthberson RA, Ferrara N et al (1999) Comparisons of the intraocular tissue distribution pharmacokinetics and safety of 125-I-Labeled Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Patholol 27:536–544

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eye Surgery Clinic, Santa Chiara Hospital, via Roma 67, 56126, Pisa, Italy

    Stanislao Rizzo, Federica Genovesi-Ebert, Emanuele Di Bartolo, Andrea Vento & Sofia Miniaci

  2. Opthalmology, Beaumont Hospital, Royal Oak, MI, USA

    George Williams

  3. via Diaz 86, 55100, Lucca, Italy

    Stanislao Rizzo

Authors
  1. Stanislao Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federica Genovesi-Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emanuele Di Bartolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Vento
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sofia Miniaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. George Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanislao Rizzo.

Additional information

This article is original and has not been published previously.

The authors have no financial interests related to this publication and transfer copyright to the publisher upon acceptance.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rizzo, S., Genovesi-Ebert, F., Di Bartolo, E. et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246, 837–842 (2008). https://doi.org/10.1007/s00417-008-0774-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0774-y

Keywords

Search

Navigation